Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice

Ono,Kazuhiko; Nimura,Satoshi; Nishinakagawa,Takuya; Hideshima,Yuko; Enjyoji,Munechika; Nabeshima,Kazuki; Nakashima,Manabu

doi:10.3892/etm.2013.1456

Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice

Authors:
- Kazuhiko Ono
- Satoshi Nimura
- Takuya Nishinakagawa
- Yuko Hideshima
- Munechika Enjyoji
- Kazuki Nabeshima
- Manabu Nakashima
View Affiliations

Affiliations: Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, Jonan-ku, Fukuoka 814-0180, Japan, Department of Pathology, Faculty of Medicine, Fukuoka University, Jonan-ku, Fukuoka 814-0180, Japan
Published online on: December 19, 2013 https://doi.org/10.3892/etm.2013.1456
Pages: 573-578

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sodium 4-phenylbutyrate (PBA) exhibits anti‑inflammatory effects by suppressing nuclear factor‑κB (NF-κB) activation. In the present study, the effects of PBA on a mouse model of dextran sulfate sodium (DSS)‑induced colitis were investigated. The therapeutic efficacy of PBA (150 mg/kg body weight) in DSS-induced colitis was assessed based on the disease activity index (DAI), colon length, the production of inflammatory cytokines and histopathological examination. The results showed an increase in the median survival time in the PBA-treated group compared with that of the untreated DSS control group. DAI scores were lower in the PBA-treated group than in the DSS control group during the 12 days of the experiment. Additionally, PBA treatment inhibited shortening of the colon and the production of the inflammatory cytokines tumor necrosis factor‑α, interleukin-1β and IL-6, which were measured in the colonic lavage fluids. Histopathological examination of the DSS control group showed diffused clusters of chronic inflammatory cells infiltrating the lamina propria, partial exfoliation of the surface epithelium and decreased numbers of mature goblet cells. By contrast, in the PBA-treated group the histopathological findings were the same as those of the normal healthy controls. These results suggest that PBA strongly prevents DSS-induced colitis by suppressing the mechanisms involved in its pathogenesis.

View Figures

View References

1	Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 115:182–205. 1998. View Article : Google Scholar : PubMed/NCBI
2	Podolsky DK: Inflammatory bowel disease. N Engl J Med. 347:417–429. 2002. View Article : Google Scholar
3	Kaser A, Zeissig S and Blumberg RS: Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010. View Article : Google Scholar
4	Pullman WE, Elsbury S, Kobayashi M, Hapel AJ and Doe WF: Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology. 102:529–537. 1992.PubMed/NCBI
5	Bouma G and Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 3:521–533. 2003. View Article : Google Scholar : PubMed/NCBI
6	Strober W, Fuss I and Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest. 117:514–521. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sartor RB: Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 3:390–407. 2006.
8	Maloy KJ and Powrie F: Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 474:298–306. 2011. View Article : Google Scholar : PubMed/NCBI
9	Scharl M and Rogler G: Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol. 28:301–309. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sands BE: Therapy of inflammatory bowel disease. Gastroenterology. 118:S68–S82. 2000. View Article : Google Scholar
11	Shteyer E and Wilschanski M: Novel therapeutic modalities in pediatric inflammatory bowel disease. Isr Med Assoc J. 10:816–820. 2008.PubMed/NCBI
12	Reddy JG and Loftus EV Jr: Safety of infliximab and other biologic agents in the inflammatory bowel disease. Gastroenterol Clin North Am. 35:837–855. 2006. View Article : Google Scholar : PubMed/NCBI
13	Katz JA: Management of inflammatory bowel disease in adults. J Dig Dis. 8:65–71. 2007. View Article : Google Scholar : PubMed/NCBI
14	Yamamoto T, Umegae S and Matsumoto K: Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 16:1905–1911. 2010. View Article : Google Scholar
15	Maestri NE, Brusilow SW, Clissold DB and Bassett SS: Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 335:855–859. 1996. View Article : Google Scholar : PubMed/NCBI
16	Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW and Dover GJ: Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 85:43–49. 1995.PubMed/NCBI
17	Mercuri E, Bertini E, Messina S, Pelliccioni M, D’Amico A, Colitto F, Mirabella M, Tiziano FD, Vitali T, Angelozzi C, et al: Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord. 14:130–135. 2004. View Article : Google Scholar : PubMed/NCBI
18	Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR and Malkin MG: Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs. 25:131–138. 2007. View Article : Google Scholar : PubMed/NCBI
19	Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE and Pahan K: Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLoS One. 7:e381132012.PubMed/NCBI
20	Luo ZF, Feng B, Mu J, Qi W, Zeng W, Guo YH, Pang Q, Ye ZL, Liu L and Yuan FH: Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation. Toxicol Appl Pharmacol. 246:49–57. 2010. View Article : Google Scholar
21	Park JS, Lee EJ, Lee JC, Kim WK and Kim HS: Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways. Int Immunopharmacol. 7:70–77. 2007. View Article : Google Scholar : PubMed/NCBI
22	Vij N, Fang S and Zeitlin PL: Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem. 281:17369–17378. 2006. View Article : Google Scholar
23	Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M and Nakashima M: A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat Disord. 15:649–654. 2009.PubMed/NCBI
24	Wirtz S, Neufert C, Weigmann B and Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2:541–546. 2007. View Article : Google Scholar : PubMed/NCBI
25	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
26	Dionne S, D’Agata ID, Hiscott J, Vanounou T and Seidman EG: Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol. 112:435–442. 1998. View Article : Google Scholar : PubMed/NCBI
27	Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI and Cominelli F: Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology. 117:806–813. 1999. View Article : Google Scholar : PubMed/NCBI
28	Kwon KH, Murakami A, Hayashi R and Ohigashi H: Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun. 337:647–654. 2005. View Article : Google Scholar : PubMed/NCBI
29	Rutgeerts P, Van Assche G and Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 126:1593–1610. 2004. View Article : Google Scholar : PubMed/NCBI
30	Yun L and Hanauer S: Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 3:235–248. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bosani M, Ardizzone S and Porro GB: Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 3:77–97. 2009.PubMed/NCBI
32	Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A and Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 348:601–608. 2003.
33	Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA and Michetti P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 124:917–924. 2003.PubMed/NCBI